GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » PB Ratio

Sumitomo Pharma Co (Sumitomo Pharma Co) PB Ratio

: 0.43 (As of Today)
View and export this data going back to 2009. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-19), Sumitomo Pharma Co's share price is $2.595. Sumitomo Pharma Co's Book Value per Share for the quarter that ended in Dec. 2023 was $6.01. Hence, Sumitomo Pharma Co's PB Ratio of today is 0.43.

The historical rank and industry rank for Sumitomo Pharma Co's PB Ratio or its related term are showing as below:

DNPUF' s PB Ratio Range Over the Past 10 Years
Min: 0.4   Med: 1.28   Max: 3.04
Current: 0.51

During the past 13 years, Sumitomo Pharma Co's highest PB Ratio was 3.04. The lowest was 0.40. And the median was 1.28.

DNPUF's PB Ratio is ranked better than
93.97% of 962 companies
in the Drug Manufacturers industry
Industry Median: 1.91 vs DNPUF: 0.51

During the past 12 months, Sumitomo Pharma Co's average Book Value Per Share Growth Rate was -45.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -8.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 0.40% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 3.70% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sumitomo Pharma Co was 12.20% per year. The lowest was -8.60% per year. And the median was 3.85% per year.

Back to Basics: PB Ratio


Sumitomo Pharma Co PB Ratio Historical Data

The historical data trend for Sumitomo Pharma Co's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.32 1.05 1.39 0.79 0.83

Sumitomo Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.83 0.59 0.52 0.52

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co PB Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's PB Ratio falls into.



Sumitomo Pharma Co PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Sumitomo Pharma Co's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=2.595/6.006
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Sumitomo Pharma Co  (OTCPK:DNPUF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Sumitomo Pharma Co PB Ratio Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description

Traded in Other Exchanges
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.